4.6 Letter

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Journal

BLOOD ADVANCES
Volume 6, Issue 2, Pages 373-375

Publisher

ELSEVIER
DOI: 10.1182/bloodadvances.2021006006

Keywords

-

Categories

Funding

  1. Novartis Pharma

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available